Piramal Pharma Solutions (PPS) is pleased to announce that it was recognized as the winner of the ‘Regulatory Procedures and Compliance’ award at the prestigious CPhI Pharma Awards (2017) on October 24 at the Intercontinental Hotel – Frankfurt, Germany. PPS competed with several of its global peers in the category. Regulatory excellence is an area that is fundamental to the needs of our end customers, and the CPhI Pharma Awards are among the most coveted recognitions in the pharmaceutical industry. It celebrates thinkers and creators that break new ground, recognizing companies that drive the industry forward. With over 200 entries submitted in 19 different award categories, the CPhI Pharma Awards serve as a great barometer for industry excellence.
Upon receiving the award, Vivek Sharma, Chief Executive Officer of Piramal Pharma Solutions said: “It is a pleasure to accept the award on behalf of all the dedicated employees at Piramal Pharma Solutions that made this recognition possible. The award serves as a testament to our efforts that advance Piramal Pharma Solutions from ‘Quality for Compliance’ to ‘Quality as a Culture’. Our ‘One Piramal’ strategy is built around the values of Customer Centricity, Quality, and Innovation. It is great to be recognized by our fellow peers and customers on one of our core values.”
“We recognize that as an industry, we serve a higher purpose: Delivering solutions for our customers that improve the standard of life and reduce the burden of disease in patients. In order to accomplish these successfully, a robust quality and regulatory compliance record is a must. We therefore take enormous pride in this recognition,” he added.
PPS is a leading global Contract Development and Manufacturing Organization (CDMO), with 12 locations in North America, Europe, and Asia, driving solutions for our customers, from discovery through commercialization. With a stellar track record that includes 34 launched products for customers, Piramal is now a ‘partner of choice’ for leading pharmaceutical and biotech firms in North America and Europe.
PPS’ global capabilities include, Discovery Chemistry Support, Drug Substance Development and Manufacturing, Formulation Development through Commercialization, and Clinical Trial Supplies. Further, Piramal is a leader in developing and manufacturing Antibody Drug Conjugates (ADCs) from early development to launch. With a commitment to investing capital that meet our customers’ future needs, a robust balance sheet, a strong management team, and a focus on customer centricity, PPS expects to continue to make a positive impact in human life for years to come.